文献速递白血病血栓与止血

急性髓系白血病患者接受含蒽环类化疗后的心脏毒性:一项基于人群的匹配队列研究

Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study.
PubMed 文献 · Br J Haematol · 2025-07-21

该研究将2000至2020年间接受含蒽环类化疗的1379例成人急性髓系白血病患者与6895例丹麦背景人群对照进行匹配,中位随访分别为11.8年和12.8年。结果显示AML患者充血性心力衰竭风险在整个随访期均高于对照,3个月时调整HR为15.0(95%CI:7.02-32.1),15年时为2.68(95%CI:1.67-4.30);非充血性心血管疾病风险初期较高但约10年后趋同。

要点

  • 含蒽环类化疗的AML患者充血性心力衰竭风险全程高于对照,3个月时调整HR为15.0。
  • 非充血性心血管疾病风险初期升高,约10年后与背景人群趋同。
  • 年龄增加和男性是AML患者充血性心力衰竭及非充血性心血管疾病的危险因素。

核心结论

  • 接受含蒽环类化疗的AML患者心血管疾病风险升高,尤其在治疗开始后的最初数年内。
  • 作者认为更关注早期检测和心脏保护策略可能有助于未来减轻蒽环类药物的有害影响。

研究设计与样本

  • 基于人群的匹配队列研究,纳入2000至2020年间接受含蒽环类化疗的1379例成人AML患者,匹配6895例丹麦背景人群对照。
  • 中位随访时间分别为11.8年和12.8年。

主要发现

  • AML患者充血性心力衰竭风险在整个随访期均高于对照,调整HR从3个月时的15.0(95%CI:7.02-32.1)降至15年时的2.68(95%CI:1.67-4.30)。
  • 非充血性心血管疾病风险初期高于对照(3个月时调整HR:9.16[95%CI:6.61-12.7]),约10年后与对照趋同。
  • 在AML患者中,年龄增加和男性被确定为充血性心力衰竭和非充血性心血管疾病的危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anthracycline-containing chemotherapy is associated with cardiovascular diseases (CVDs). While knowledge regarding the extent of cardiotoxicity in adult patients with acute myeloid leukaemia (AML) is sparse, anthracyclines remain a key component in the treatment. To address this, 1379 adult AML patients treated with anthracycline-containing chemotherapy between 2000 and 2020 were matched to 6895 comparators from the Danish background population and followed for a median of 11.8 and 12.8 years respectively. The risk of congestive heart failure (CHF) was higher in AML patients compared to the comparators throughout the entire follow-up period with adjusted hazard ratios (HRs) ranging from 15.0 (95% CI: 7.02-32.1) after 3 months to 2.68 (95% CI: 1.67-4.30) after 15 years. The risk of non-CHF CVD was initially higher in AML patients (adjusted HR: 9.16 [95% CI: 6.61-12.7] after 3 months) but converged to that of the comparators after approximately 10 years. Among AML patients, increasing age and male sex were identified as risk factors of CHF and non-CHF CVD. In summary, AML patients treated with anthracycline-containing chemotherapy had an elevated risk of CVD, particularly during the first years after treatment initiation. Increased focus on early detection and cardioprotective strategies may help mitigate the harmful effects of anthracyclines in the future.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jensen RH, Teglgaard C, Jensen JF, et al. Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study. Br J Haematol. 2025. PMID: 40692261. doi:10.1111/bjh.70026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。